Efficacy of post‐first‐line agents for advanced gastrointestinal stromal tumors following imatinib failure: A network meta‐analysis

Abstract Background Imatinib is the standard first‐line treatment for advanced gastrointestinal stromal tumors (GISTs); however, most patients eventually develop imatinib resistance, leading to considerable clinical challenges. Few direct comparisons have been made between different post‐first‐line...

Full description

Bibliographic Details
Main Authors: Kehan Hu, Hu Zhang, Mingrong Shu, Xingyue Wang
Format: Article
Language:English
Published: Wiley 2023-06-01
Series:Cancer Medicine
Subjects:
Online Access:https://doi.org/10.1002/cam4.5912